US Court rules in favour of Impax Laboratories in Wellbutrin SR patent case
GlaxoSmithKline announced that the US Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour of Impax Laboratories Inc, and upheld a lower court ruling that Impax's generic product did not infringe GSK's US patent for its antidepressant Wellbutrin SR.
GSK continues to be committed to Wellbutrin XL - its once daily version of Wellbutrin launched last fall -- which now represents nearly 40 per cent of new prescriptions being written for Wellbutrin (XL & SR).